Pelvis Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Pelvis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 2Phase 3

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Renal Pelvis and Ureter Urothelial Carcinoma
National Cancer Institute (NCI)249 enrolled257 locationsNCT04628767
Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled491 locationsNCT05987241
Recruiting
Phase 2

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NeoplasmsClear Cell Renal Cell CarcinomaMalignant Neoplasms+1 more
Yonsei University78 enrolled1 locationNCT07469683
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled399 locationsNCT06661720
Recruiting
Not Applicable

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Urothelial CarcinomaBladder CancerUpper Tract Urothelial Carcinoma+1 more
University of Washington128 enrolled1 locationNCT06040762
Recruiting
Phase 4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Metastatic Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Metastatic Renal Pelvis and Ureter Urothelial Carcinoma+4 more
Mayo Clinic75 enrolled1 locationNCT06764095
Recruiting
Phase 2

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma
Jonsson Comprehensive Cancer Center21 enrolled1 locationNCT05775471
Recruiting
Phase 3

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Transitional Cell Cancer of Renal Pelvis and Ureter
Steba Biotech S.A.100 enrolled18 locationsNCT04620239
Recruiting
Not Applicable

Pelvis Adaptive Radiotherapy (ART)

Pelvis Neoplasms
Royal North Shore Hospital280 enrolled1 locationNCT06650033
Recruiting

Bladder EpiCheck European Haematuria Study

Urothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and UreterHematuria+2 more
Nucleix Ltd.800 enrolled5 locationsNCT06818136
Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Malignant Solid NeoplasmRecurrent Prostate CarcinomaStage IV Bladder Cancer AJCC v7+8 more
University of Washington1,500 enrolled1 locationNCT01050504
Recruiting

ENDOMETRIOSIS - MRI

Mobility LimitationDiagnosisMagnetic Resonance Imaging+3 more
University Hospital, Lille52 enrolled1 locationNCT05779462
Recruiting
Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Stage IV Bladder Cancer AJCC v7Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial Carcinoma+3 more
Mayo Clinic70 enrolled1 locationNCT07087860
Recruiting
Phase 1Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Metastatic Urothelial CarcinomaUrothelial CancerBladder Cancer+1 more
Dana-Farber Cancer Institute106 enrolled1 locationNCT04724018
Recruiting
Phase 1

Adaptive Radiation for Abdominopelvic Metastases

Neoplasm - Soft Tissue Pelvis Malignant SecondaryMalignant Neoplasm of Stomach
Fox Chase Cancer Center30 enrolled1 locationNCT05880667
Recruiting
Phase 2Phase 3

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

Urothelial Carcinoma of the Renal Pelvis and UreterTransitional Cell Cancer of the Renal Pelvis and Ureter
University of British Columbia70 enrolled4 locationsNCT06124976
Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Phase 2

Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

Urothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma Urethra+1 more
Nagoya University43 enrolled1 locationNCT06983210
Recruiting
Phase 2

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Bladder AdenocarcinomaBladder Squamous Cell CarcinomaMetastatic Bladder Carcinoma+8 more
Emory University25 enrolled4 locationsNCT05756569
Recruiting
Phase 3

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Urothelial Cancer of Renal PelvisUrothelial Carcinoma Ureter
University of Texas Southwestern Medical Center132 enrolled1 locationNCT04865939